The research program in the Liu Laboratory focuses on the dynamic interactions between
tumor cells and immune cells in the tumor microenvironment. At the molecular level,
we aim at elucidating the mechanisms underlying genetic and epigenetic regulation
of expression of tumor suppressors and immune checkpoints, including IRF8, Fas, PD-L1,
and OPN, in tumor cells and myeloid cells. At the cellular level, we study tumor cell
and myeloid cell interactions with the tumor-specific cytotoxic T lymphocytes (CTLs)
in the context of CTL immune suppression. Our long-term goal is to develop molecular
target-based immunotherapies to enhance human cancer immune surveillance to treat
human cancer.
Selected recent publications
Dakota B. Poschel, John D. Klement, Alyssa D. Merting, Chunwan Lu, Yang Zhao, Dafeng
Yang, Wei Xiao, Huabin Zhu, Ponnala Rajeshwari, Michael Toscano, Kimya Jones, Amanda
Barrett, Roni J. Bollag, Padraic G. Fallon, Huidong Shi, and Kebin Liu. 2024. PD-L1 Restrains PD-1+Nrp1lo Treg Cells to Suppress Inflammation-driven Colorectal Tumorigenesis. Cell Reports. In Press.
John D Klement, Priscilla S Redd, Chunwan Lu, Alyssa D Merting, Dakota B Poschel,
Dafeng Yang, Natasha M Savage, Gang Zhou, David H Munn, Padraic G Fallon, Kebin Liu. 2023. Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic
T lymphocyte recruitment. Cancer Cell. 41:620-636.e9.
Aaron H Colby, Jack Kirsch, Amit N Patwa, Rong Liu, Beth Hollister, William McCulloch,
Joanna E Burdette, Cedric J Pearce, Nicholas H Oberliels, Yolonda L Colson, Kebin Liu, Mark W Grinstaff. 2023. Radiolabeled Biodistribution of Expansile Nanoparticles:
Intraperitoneal Administration Results in Tumor Specific Accumulation. ACS Nano. 17:2212-2221.
Zeinab Y. Al Subeh, Dakota B. Poschel, Priscilla S. Redd, John D. Klement, Alyssa
D. Merting, Dafeng Yang, Megh Mehta, Huidong Shi, Yolonda L. Colson, Nicholas H. Oberlies,
Cedric J. Pearce, Aaron H. Colby, Mark W. Grinstaff, and Kebin Liu. 2022. Lipid nanoparticle delivery of Fas plasmid restores Fas expression to suppress
melanoma growth in vivo. ACS Nano. 16:12695-12710.
Chunwan Lu, Dafeng Yang, John D. Klement, Yolonda L Colson, Nicholas H Oberlies, Cedric
J Pearce, Aaron H Colby, Mark W Grinstaff, Zhuoqi Liu, Huidong Shi, Han-Fei Ding,
Kebin Liu. 2022. H3K9me3 represses G6PD expression to suppress the pentose phosphate pathway
and ROS production to promote human mesothelioma growth. Oncogene. 41:2651-2662.
Chunwan Lu, Dafeng Yang, Klement, John, Yolonda L. Colson, Nicholas H Oberlies, Cedric
J Pearce Aaron H. Colby, Mark W Grinstaff Hanfei Ding, Huidong Shi, and Kebin Liu. 2022. G6PD functions as a metabolic checkpoint to regulate granzyme B expression
in tumor-specific cytotoxic T lymphocytes. J Immunother Cancer. 10:e003541. PMCID: PMC8753452.
Chunwan Lu, Zhuoqi Liu, John D Klement, Dafeng Yang, Alyssa D Merting, Dakota Poschel,
Thomas Albers, Jennifer L Waller, Huidong Shi, Kebin Liu. 2021. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1
function to promote pancreatic cancer immune escape. J Immunother Cancer. 9:e002624.
Huabin Zhu, John D Klement, Chunwan Lu, Priscilla S Redd, Dafeng Yang, Alyssa D Smith,
Dakota B Poschel, Juan Zou, Ding Liu, Peng George Wang, David Ostrov, Nicolas Coant,
Yusuf A Hannun, Aaron H Colby, Mark W Grinstaff, Kebin Liu. 2021. Asah2 Represses the p53-Hmox1 Axis to Protect Myeloid-Derived Suppressor Cells
from Ferroptosis. J Immunol. 206:1395-1404.
Chunwan Lu, John D Klement, Alyssa D Smith, Dafeng Yang, Jennifer L Waller, Darren
D Browning, David H Munn, Kebin Liu. 2020. p50 suppresses cytotoxic T lymphocyte effector function to regulate tumor
immune escape and response to immunotherapy. J Immunother Cancer. 8:e001365.
Alyssa D Smith, Chunwan Lu, Daniela Payne, Amy V Paschall, John D Klement, Priscilla
S Redd, Mohammed L Ibrahim, Dafeng Yang, Qimei Han, Zhuoqi Liu, Huidong Shi, Thomas
J Hartney, Asha Nayak-Kapoor, Kebin Liu. 2020. Autocrine IL6-mediated Activation of the STAT3-DNMT Axis Silences the TNFα-RIP1
Necroptosis Pathway to Sustain Survival and Accumulation of Myeloid-Derived Suppressor
Cells. Cancer Res. 80:3145-3156.
Christopher Gromisch, Motaz Qadan, Mariana Albuquerque Machado, Kebin Liu, Yolonda Colson, Mark W Grinstaff. 2020. Pancreatic Adenocarcinoma: Unconventional
Approaches for an Unconventional Disease. Cancer Res. 80:3179-3192.
Chunwan Lu,John D. Klement, Wei Xiao, Mohammed Ibrahim, Priscilla S. Redd, Asha Nayak-Kapoor,
Gang Zhou, and Kebin Liu. 2019. Type I IFNs activates STAT3 to regulate effector expression of cytotoxic T
lymphocyte effectors to suppress tumor development. J Immunother Cancer. 7:157.
Chunwan Lu, Dafeng Yang, John D. Klement, II Kyu Oh, Natasha M. Savage, Jennifer L.
Waller, Aaron H. Colby, Mark W. Grinstaff, Nicholas H. Oberlies, Cedric J. Pearce,
Zhiliang Xie, Samuel K. Kulp, Christopher C. Coss, Mitch A. Phelps, Thomas Albers,
Iryna O. Lebedyeva, and Kebin Liu. 2019. SUV39H1 represses the expression of cytotoxic T lymphocyte effectors to promote
colon tumor immune evasion. Cancer Immunol. Res. 7:414-427.
John D. Klement, Amy V. Paschall, Priscilla S. Redd, Mohammed L. Ibrahim, Chunwan
Lu, Dafeng Yang, Esteban Celis, Scott I. Abrams, Keiko Ozato, and Kebin Liu. 2018. An Osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion. J Clin Invest. 128:5549-5560.
Mohammed L. Ibrahim, John D. Klement, Chunwan Lu, Priscilla S. Redd, Wei Xiao, Dafeng
Yang, Darren D. Browning, Natasha M. Savage, Phillip J. Buckhaults, Herbert C. Morse
III, and Kebin Liu. 2018. Myeloid-Derived Suppressor Cells Produce IL-10 to Elicit DNMT3b-Dependent
IRF8 Silencing to Promote Colitis-Associated Colon Tumorigenesis. Cell Rep. 25:3036-3046.
Priscilla S. Redd, Mohammed Ibrahim, Sarah K. Sharman, Amy V. Paschall, Dafeng Yang,
Asha Nayak-Kapoor, and Kebin Liu. 2017. SETD1B activate iNOS expression in myeloid-derived suppressor cells. Cancer Res. 77:2834-2843.
Chunwan Lu, Asif Talukder, Natasha Savage, Nagendra Singh and Kebin Liu. 2017. Jak-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation
to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. OncoImmunology. 6:e1291106.
Chunwan Lu, Amy V. Paschall, Huidong Shi, Natasha Savage, Jennifer L. Waller, Maria
E. Sabbatini, Nicholas H. Oberlies, Cedric Pearce, Kebin Liu. 2017. The MLL1-H3K4me3 Axis-Mediated Up-Regulation of PD-L1 Contributes to Pancreatic
Cancer Immune Evasion. J Natl Cancer Inst (JNCI) 109:djw283.
